Tandil, Argentina - The first implantation of the Castor™ Branched Aortic Stent-Graft System (the “Castor™ Stent”) developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”), was recently completed in Argentina. This marks the stent’s introduction in its third overseas market after Poland and Spain, and the first one in South America.
The implantation, led by Dr. Marcelo Brizio and Dr. Alejandro Cuacci of the Clínica Nueva Chacabuco de Tandi Hospital, was performed on a 61-year-old male admitted with sudden retrosternal pain and an underlying condition of hypertension. Following in-depth discussions, the surgical team decided that the Castor™ Stent, in combination with Endovastec™’s Hercules™ Low Profile Tubular Stent-Graft System ("Hercules™-LP Stent") for the endoluminal repair, would make the most efficient treatment tools.
Miao Zhenghua, President of Endovastec™, noted, “The first clinical implantation of the Castor™ Stent in Argentina marks the entry of Endovastec™ technology for the reconstruction of aortic arch branches into the South American region. Endovastec™ will continue to strengthen its cooperation with overseas clinical experts to introduce more high-quality, innovative and sophisticated medical devices to South America, in order to provide more options for local doctors and patients in the field of aortic and peripheral vascular diseases treatment.”
The procedure involved reconstructing the left subclavian artery (LSA) with the Castor™ Stent to seal the primary tears. The Hercules®-LP Stent successfully sealed the secondary tears and opened the distal true lumen to restore blood flow. Postoperative imaging showed that the stent-graft was precisely positioned and the blood flow to the LSA was restored. Additionally, the proximal multi-mini springs of the Castor™ Stent had sealed effectively without any endoleak.
The team of experts gave the Castor™ Stent their full approval, both for its innovative unibody design, which addresses the challenge of LSA reconstruction, and for its postoperative efficacy.
About Endovastec™ Castor™ Stent
Castor™ Stent, developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (00853.HK), is the stent-graft system for simultaneous aorta and aortic arch repair through minimally invasive treatment. Its unique unibody structure can adapt to a variety of arch anatomies and allows one-off access and release, ensuring safe and convenient rebuilding of the left subclavian artery and long-term stability, all while reducing the incidence of endoleaks. Castor™ Stent has entered more than 500 hospitals in China since its launch, and its innovative features have won recognition by clinical experts.